Bio Green Med Solution (BGMS) Q1 2026 earnings summary

Executive summary

• Shifted core business from biopharmaceuticals to fire safety equipment and services after acquiring Fitters Sdn. Bhd. in September 2025, now focused on the Malaysian fire safety market and generating $0.8 million in Q1 2026 product revenue.

• Deconsolidated UK subsidiary Cyclacel Limited in January 2025, resulting in a $5.0 million gain from discontinued operations.

• All research and development activities discontinued following asset sales and subsidiary liquidation.

• General and administrative expenses dropped by $3.8 million year-over-year due to one-time costs in 2025 and cost discipline.

• Maintains $3.3 million in cash and cash equivalents, expected to fund operations into Q4 2026.

Financial highlights

• Revenue for Q1 2026 was $778,000–$0.8 million, up from $0 in Q1 2025, driven by fire safety product sales.

• Net loss for Q1 2026 was $197,000–$0.2 million, compared to a net loss of $81,000–$0.1 million in Q1 2025.

• Gross margin for Q1 2026 was approximately 23%.

• General and administrative expenses were $389,000–$0.4 million in Q1 2026, down from $4.2 million in Q1 2025.

• Cash and cash equivalents stood at $3.3 million as of March 31, 2026.

Outlook and guidance

• Revenues in fire safety expected to grow modestly in the near term, with higher growth anticipated from data center expansion in Southern Malaysia.

• General and administrative expenses projected to remain lower due to absence of prior year’s non-recurring costs.

• Current cash resources are projected to fund planned expenditures into Q4 2026.

• Focus remains on scaling fire safety operations and expanding product and service offerings.

• Substantial doubt remains about ability to continue as a going concern beyond Q4 2026 without additional funding.